Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV (SHINY)

3. juni 2014 opdateret af: Chengdu Kanghong Biotech Co., Ltd.

The Safety and Efficacy of Conbercept in the Treatment of Choroidal Neovascularization (CNV) Secondary to High Myopia

This study is design to evaluate the effect of conbercept therapy on visual acuity and anatomic outcomes compared to sham injection and durability of response observed in subjects with choroid neovascularization secondary to pathological myopia.

Studieoversigt

Status

Ukendt

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

176

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Kina
    • Beijing
      • Beijing, Beijing, Kina, 100083
        • Peking University Third Hospital
      • Beijing, Beijing, Kina, 100032
        • Peking Union Medical College Hospital
      • Beijing, Beijing, Kina, 100730
        • Beijing Tongren Hospital Affiliated to Capital Medical University
    • Chongqing
      • Chongqing, Chongqing, Kina, 400038
        • Southwest Hospital
      • Chongqing, Chongqing, Kina, 400042
        • Daping Hospital, Research Institute of Surgery Third Military Medical University
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510060
        • Zhongshan Ophthalmic Center
    • Hubei
      • Wuhan, Hubei, Kina, 430070
        • Wuhan General Hospital of Guangzhou Military
    • Jiangsu
      • Wuxi, Jiangsu, Kina, 214002
        • Wuxi No.2 People's Hospital
    • Shandong
      • Qingdao, Shandong, Kina, 266071
        • Ophthalmologic Hospital of Qingdao
    • Shanghai
      • Shanghai, Shanghai, Kina, 200080
        • Shanghai First People's Hospital
    • Shanxi
      • Xian, Shanxi, Kina, 710032
        • Xijing Hospital
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • West China Hospital of Sichuan University
    • Zhejiang
      • Wenzhou, Zhejiang, Kina, 325027
        • The Affiliated Eye Hospital of WMC

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Patients give fully informed consent and are willing and able to comply with all study procedures.

  2. In the study eye:

    • Myopia of equal to or greater than -6.00D,and axial length ≥26.5mm.
    • Diagnosis of active subfoveal, juxafoveal, or extrafoveal CNV secondary to high myopia.
    • Visual impairment due to CNV secondary to high myopia.
    • BCVA score ≥24 and ≤73 ETDRS letters (approximately 20/40~ 20/320 Snellen equivalent).
    • Ocular media of sufficient quality to obtain fundus and OCT images.
  3. The BCVA score of fellow eyes ≥ 19 ETDRS letters (approximately 20/400 Snellen equivalent)

Exclusion Criteria:

  1. Current vitreous hemorrhage in either eye.
  2. Intraocular treatment with corticosteroids within last 3 months or periocular treatment with corticosteroids within last month in the study eye.
  3. Active infectious ocular inflammation in either eye.
  4. Fibrosis or atrophy involving the center of foveal in the study eye.
  5. Any concurrent intraocular condition in the study eye that, in the opinion of investigator, could either require medical or surgical intervention during the study period to prevent or treat visual loss that might result from that condition.
  6. The lesion size ≥30 mm2 in the study eye.
  7. Any ocular disorder in the study eye that, in the opinion of the investigator, may confound interpretation of the study results.
  8. Uncontrolled glaucoma or cup/disk ratio > 0.8 in the study eye.
  9. Aphakia (excluding artificial lens) in the study eye.
  10. Serious amblyopia and amaurosis in the fellow eye.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: conbercept treatment group
Subjects will receive conbercept injections at a dose of 0.5 mg/eye, once a month for first 3 months. In the next 6 months, the investigator will decide whether repeat injections are needed base on the monthly assessment results.
Medicin: conbercept, Fixed
intravitreal injection of 0.5 mg conbercept per month, fixed injection
Medicin: conbercept, PRN
intravitreal injection of 0.5 mg conbercept as need, PRN
Sham-komparator: sham injection group
Subjects will receive sham injections monthly for 3 months and will receive 0.5 mg/eye conbercept at month 4. The investigator will decide whether repeat injections are needed base on the monthly assessment results from month 5 to month 9.
Medicin: conbercept, Fixed
intravitreal injection of 0.5 mg conbercept per month, fixed injection
Medicin: conbercept, PRN
intravitreal injection of 0.5 mg conbercept as need, PRN
Andet: sham injection
sham intravitreal injection per month, fixed injection

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
mean change from baseline of visual acuity
Tidsramme: 3-month
to compare the mean change from baseline of best-corrected visual acuity (BCVA) between conbercept treatment group and sham injection group at month 3
3-month

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
mean change from baseline of anatomical features
Tidsramme: 3-month
to compare the difference of mean change from baseline of CRT, CNV size and lesion size between conbercept treatment group and sham injection group at month 3
3-month
mean change from baseline of visual acuity
Tidsramme: 9 months
to evaluate the mean change from baseline of BCVA of two groups from month 1 to month 9
9 months
safety and tolerability of conbercept
Tidsramme: 3-month and 9-month
to evaluate the incidence of AEs (ocular or non-ocular) of two groups at month 3 and 9
3-month and 9-month

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Chengdu Kanghong Biotech Co., Ltd.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. august 2012

Primær færdiggørelse (Faktiske)

1. februar 2014

Studieafslutning (Forventet)

1. marts 2015

Datoer for studieregistrering

Først indsendt

11. marts 2013

Først indsendt, der opfyldte QC-kriterier

11. marts 2013

Først opslået (Skøn)

12. marts 2013

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

4. juni 2014

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. juni 2014

Sidst verificeret

1. marts 2014

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • KHSWKH902007

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med conbercept, Fixed

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Croatia

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner